{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:16:09Z","timestamp":1791353769863,"version":"4.3.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.05.002","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"431-443","source":"Crossref","is-referenced-by-count":41,"title":["Current role of stem cell transplantation in chronic myeloid leukaemia"],"prefix":"10.1016","volume":"22","author":[{"given":"Alois","family":"Gratwohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Heim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2009.05.002_bib1","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.05.002_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-104-2-155","article-title":"Marrow transplantation for the treatment of chronic myelogenous leukaemia","volume":"104","author":"Thomas","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2009.05.002_bib4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukaemia \u2013 advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.05.002_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0037-1963(03)70039-0","article-title":"Prognostic factors in chornic myeloid leukaemia: allografting","volume":"40","author":"Gratwohl","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.beha.2009.05.002_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(70)92874-6","article-title":"Complication of bone marrow transplantation. Graft-versus-host disease resulting from chronic-myelogenous-leukaemia leucocyte transfusions","volume":"15","author":"Graw","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.05.002_bib7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJM197504242921706","article-title":"Bone marrow transplantation (second of two parts)","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.05.002_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","article-title":"Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase","volume":"101","author":"Or","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib9","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJM197707212970307","article-title":"Cure of hematologic neoplasia with transplantation of marrow from identical twins","volume":"297","author":"Fefer","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.05.002_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(84)92179-2","article-title":"Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia","volume":"8378","author":"Speck","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.05.002_bib12","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1056\/NEJM198105213042105","article-title":"Chronic myelogenous leukemia \u2013 new concepts (second of two parts)","volume":"304","author":"Koeffler","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.05.002_bib13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(82)92736-2","article-title":"Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia","volume":"2","author":"Goldman","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.05.002_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(82)92735-0","article-title":"Treatment of chronic granulocytic leukaemia in chronic phase by allogenei marrow transplantation","volume":"2","author":"Clift","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.05.002_bib15","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood-2002-03-0675","article-title":"Current trends in hematopoietic stem cell transplantation in Europe","volume":"100","author":"Gratwohl","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib16","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.05.002_bib17","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.05.002_bib18","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.05.002_bib19","first-page":"S5","article-title":"Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry","volume":"17","author":"Horowitz","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2009.05.002_bib20","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib21","unstructured":"Gratwohl A, Stern R, Brand R, et\u00a0al. Risk score for outcome after allogeneic haematopoietic stem cell transplantation. A retrospective anaysis. Cancer, in press."},{"key":"10.1016\/j.beha.2009.05.002_bib22","doi-asserted-by":"crossref","unstructured":"Ljungmen P, Bregni M, Brune M, et\u00a0al. Allogeneic and autologous transplantation for haematological diseases, solid tumors and immune disorders: current practice in Europe 2009. Bone Marrow Transplant, in press.","DOI":"10.1038\/bmt.2009.141"},{"key":"10.1016\/j.beha.2009.05.002_bib23","unstructured":"Dickinson AM, Pearce KF, Norden J, et-al. Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukaemia. Blood, submitted for publication."},{"key":"10.1016\/j.beha.2009.05.002_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbmt.2008.12.498","article-title":"Impacts of pretransplant comorbidities on allogeneic hematopoietic cell transplantation (HCT) outcomes","volume":"15","author":"Sorror","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2009.05.002_bib25","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1182\/blood-2008-04-148130","article-title":"Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia","volume":"112","author":"Mohty","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib26","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1016\/j.molimm.2008.04.016","article-title":"KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients","volume":"45","author":"Van der Meer","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.beha.2009.05.002_bib27","first-page":"1810","article-title":"Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukaemia. The German CML Study Group","volume":"91","author":"Gale","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib28","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib29","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood.V94.11.3668","article-title":"Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure","volume":"94","author":"Hehlmann","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib30","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.V82.7.2235.2235","article-title":"Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase","volume":"82","author":"Goldman","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib31","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.05.002_bib32","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib33","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.05.002_bib34","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/leu.2008.160","volume":"23","author":"Shimoni","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.05.002_bib36","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-\u03b1-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.05.002_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.leu.2404100","article-title":"Cytogenetic response to prior treatment with interferon-\u03b1 is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukaemia","volume":"20","author":"Maywald","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.05.002_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.bmt.1705104","article-title":"Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003","volume":"36","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2009.05.002_bib39","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.05.002_bib40","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1182\/blood-2006-05-024042","article-title":"Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation","volume":"108","author":"Schmitz","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib41","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood.V99.4.1130.h8001130_1130_1135","article-title":"Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia","volume":"99","author":"Elmaagacli","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib42","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.bbmt.2007.08.006","article-title":"Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival","volume":"13","author":"Eapen","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2009.05.002_bib43","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2007-04-085969","article-title":"Long-term follow-up of allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia","volume":"110","author":"Kebriaei","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib44","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V85.8.2263.bloodjournal8582263","article-title":"Allogeneic bone marrow tranplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM)","volume":"85","author":"Devergie","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib46","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/sj.bmt.1705996","article-title":"The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model","volume":"41","author":"Sadeghi","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2009.05.002_bib47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(04)16652-X","article-title":"Smarter rather than stronger treatment of haematological malignancies and non-malignant indications for stem-cell transplantation","volume":"364","author":"Slavin","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.05.002_bib48","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1365-2141.2001.03074.x","article-title":"Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis","volume":"115","author":"Bornhauser","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2009.05.002_bib50","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib51","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/sj.leu.2403730","article-title":"Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML","volume":"19","author":"Kerbauy","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.05.002_bib52","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1182\/blood-2007-10-118141","article-title":"Complete molecular responses are achieved after reduced intensity stem cell.transplantation and donor lymphocyte infusion in chronic myeloid leukemia","volume":"111","author":"Heaney","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib53","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1182\/blood.V100.12.3877","article-title":"Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia","volume":"100","author":"Gratwohl","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib54","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-108-6-806","article-title":"Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion","volume":"108","author":"Goldman","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2009.05.002_bib55","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bmt.1703530","article-title":"In vivo T-cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host-disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors","volume":"29","author":"Kroger","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2009.05.002_bib56","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.1999.17.2.561","article-title":"Comparative outcomes of T-cell depleted and non-T-cell depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusions","volume":"17","author":"Sehn","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.05.002_bib57","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1182\/blood-2002-03-0984","article-title":"Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life and costs","volume":"100","author":"Lee","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bbmt.2005.09.010","article-title":"Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective Phase II study","volume":"12","author":"Chalandon","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2009.05.002_bib59","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bbmt.2008.10.013","article-title":"Regulatory mechanisms in graft-versus-host responses","volume":"15","author":"Edinger","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2009.05.002_bib60","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/j.1600-6143.2008.02374.x","article-title":"Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation","volume":"10","author":"Stern","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.beha.2009.05.002_bib61","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2141.2001.03155.x","article-title":"Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse","volume":"115","author":"Mughal","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2009.05.002_bib62","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1182\/blood.V87.10.4473.bloodjournal87104473","article-title":"Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation","volume":"87","author":"Lin","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib63","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukaemia: an attempt to define patients who may not require further therapy","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib64","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.bmt.1701729","article-title":"Relapse o chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation","volume":"23","author":"Yong","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2009.05.002_bib65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib66","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib67","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.V100.2.397","article-title":"Donor lymphocyte infusion for relapsed chronic myelogenous leukaemia: prognostic relevance of the initial cell dose","volume":"100","author":"Guglielmi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib68","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.05.002_bib69","first-page":"3328","article-title":"Risk assessment in patients with Ph+ chronic myelogenous leukaemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"95","author":"Guglielmi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib70","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib71","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Olavarria","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib72","first-page":"565","article-title":"Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis","volume":"128","author":"Wang","year":"2007","journal-title":"Int J Clin Pathol"},{"key":"10.1016\/j.beha.2009.05.002_bib73","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1309\/ECDWCRLG889K1GGD","article-title":"Clinical and pathologic analysis of 16 cases of relapsed chronic myeloid leukaemia after stem cell transplantation","volume":"128","author":"Huang","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beha.2009.05.002_bib74","first-page":"443","volume":"54","author":"Faber","year":"2007","journal-title":"Neoplasma"},{"key":"10.1016\/j.beha.2009.05.002_bib75","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"European Leukemia Net. Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.05.002_bib76","unstructured":"Saussele S, Lauseker M, Gratwohl A, et\u00a0al. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: High Survival Rate Following Allogeneic HSCT after Imatinib Failure: Results of the German CML Study IV. ASH Annual Meeting Abstracts 112: 448, 2008."},{"key":"10.1016\/j.beha.2009.05.002_bib77","article-title":"Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia","volume":"19","author":"Holowiecki","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2009.05.002_bib78","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/sj.leu.2404509","article-title":"Hematopoietic stem cell transplants for chronic myeloid leukaemia in Europe \u2013 impact of cost considerations","volume":"21","author":"Gratwohl","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.05.002_bib79","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.leu.2404534","article-title":"Do affluent societies have the only options for the best therapy?","volume":"21","author":"Gajewski","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.05.002_bib80","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1053\/j.seminhematol.2007.08.003","article-title":"Autologous stem cell transplantation in chronic myeloid leukemia","volume":"44","author":"Olavarria","year":"2007","journal-title":"Semin Hematol"},{"key":"10.1016\/j.beha.2009.05.002_bib81","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/10428190701799043","article-title":"Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow and apheresis products","volume":"49","author":"Gordon","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2009.05.002_bib82","unstructured":"Rea D, Raffoux E, Cayuela JM, et\u00a0al. Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia. Leukemia, in press."},{"key":"10.1016\/j.beha.2009.05.002_bib83","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/sj.leu.2404178","article-title":"Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous imatinib therapy in patients with blast crisis chronic myeloid leukaemia","volume":"20","author":"Heim","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.05.002_bib84","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, inferferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib85","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolvine concepts in the management of chronic myeloid leucemia: recommendations from an expert panel on behalf of the European Leukemia Net","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib86","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.002_bib87","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1200\/JCO.2008.18.7740","article-title":"HLA-identical sibling compared with 8\/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia","volume":"27","author":"Arora","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.05.002_bib88","first-page":"138","article-title":"Treatment of blastic transofmration of chronic granulocytic leukaemia b high dose cyclophosphamide, total body irradiation and infusion of cryopreserved autologous marrow","volume":"2","author":"Buckner","year":"1974","journal-title":"Exp Hematol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T06:06:59Z","timestamp":1634278019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1521692609000267"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.05.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}